SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after rising sharply despite a Q3 revenue and EPS miss: traders are focusing on premium subscribers exceeding guidance, gross margin edging above expectations, and a stronger Q4 operating-income outlook. Bulls see the outlook and subscriber growth as outweighing the misses, while skeptics point to rising expenses and weaker cash flow.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional push, including its institutional-market launch, new leadership, and plans tied to tokenized assets and DeFi. Traders see these developments as potential growth drivers, while others remain frustrated that COMP has lagged broader crypto and struggled to sustain gains.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put pressure on Precigens PAPZIMEOS and sparked debate over how much competition it will bring. Traders weigh Inovios potential treatment advantages against Precigens commercial head start and full-approval status, while questioning the rivals accelerated-approval and commercialization path.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio shares fell sharply despite a Q3 beat and raised full-year outlook, as traders focused on slower Q4 organic growth guidance and concerns about decelerating messaging growth and customer expansion. The community is split between viewing the selloff as an overreaction and expecting further downside as investors reprice the growth outlook.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, driven by Dupixent and Eylea HD, sparked a sharp rally and a new 52-week high. Traders largely welcomed the results and discussed the breakouts durability, with some watching for a pullback after the fast advance.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHDs strong performance and fresh highs are drawing attention as traders describe a rotation from volatile tech and AI stocks into dividend-paying value funds for defensive exposure. Long-term holders are celebrating and adding shares, while some caution the rally may be stretched and note that rising Treasury yields can pressure dividend ETFs.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

A broader market and technology-stock selloff is weighing on QQQI, prompting many income-focused traders to buy the dip while others are moving to cash or questioning the funds downside and NAV risks. The discussion also centers on its monthly option-income distributions and the trade-off between cash flow and capped upside.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is drawing attention amid reports of a deepening China equity selloff, with traders pointing to a prolonged bear market, weak domestic demand and property-sector strain; AI export-control uncertainty is adding to the concern. Most comments are bearish, though some traders see the depressed prices as a potential bottom or value opportunity.

Carpenter Technology Corp. engages in the manufacturing, fabrication, and distribution of specialty metals. It operates through the Specialty Alloys Operations and Performance Engineered Products segments. The Specialty Alloys Operations segment is composed of its major premium alloy and stainless-steel manufacturing operations. The Performance Engineered Products segment includes the Dynamet titanium, Carpenter Additive, and the Latrobe and Mexico distribution businesses. The company was founded by James Carpenter in 1889 and is headquartered in Philadelphia, PA.

Carpenter Technology Corp.

Carpenter Technologys latest quarterly report has sparked a sharp selloff despite profit coming in above expectations: revenue missed, the full-year outlook was maintained, and higher capital spending weighed on free cash flow. Bulls call the drop an oversold reaction to strong aerospace and defense demand, while bears focus on the cautious outlook and cash-flow pressure.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax shares are drawing attention after axatilimabs Phase 2 MAXPIRe trial in idiopathic pulmonary fibrosis missed its primary endpoint, prompting the company to discontinue development in IPF. The failure triggered a sharp selloff, while some traders argue it does not affect the approved leukemia and chronic GVHD drugs or their ongoing studies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
